Karen L. Klugo, MD

Articles by Karen L. Klugo, MD

BCMA-Targeting Therapies for RRMM: Future Perspectives

BySagar Lonial, MD,Karen L. Klugo, MD,Natalie Callander, MD

March 28th 2022

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Sequencing BCMA-Targeted Therapies in RRMM

BySagar Lonial, MD,Karen L. Klugo, MD,Natalie Callander, MD

March 28th 2022

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

BCMA-Targeting Bispecifics for the Treatment of RRMM

BySagar Lonial, MD,Karen L. Klugo, MD,Natalie Callander, MD

March 28th 2022

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

CAR T-Cell Therapy for RRMM

BySagar Lonial, MD, FACP,Karen L. Klugo, MD,Natalie Callander, MD

March 21st 2022

Implications for treating patients with relapsed/refractory multiple myeloma with CAR T cells vs antibody-drug conjugates.

Treatment of Keratopathy Associated with Belantamab Mafodotin

BySagar Lonial, MD, FACP,Karen L. Klugo, MD,Natalie Callander, MD

March 21st 2022

Recommendations for managing ocular toxicities associated with belantamab mafodotin when used as treatment for relapsed/refractory multiple myeloma.

Belantamab Mafodotin Dosing Strategies in Patients with RRMM

BySagar Lonial, MD,Karen L. Klugo, MD,Natalie Callander, MD

March 14th 2022

What to know in terms of dosing belantamab mafodotin treatment in patients with relapsed/refractory multiple myeloma.

Selecting Appropriate Treatment for Patients With Heavily Pretreated Multiple Myeloma

BySagar Lonial, MD,Karen L. Klugo, MD,Natalie Callander, MD

March 14th 2022

Variables that impact treatment decisions for relapsed/refractory multiple myeloma.

Management of a 61-Year-Old Female With Heavily Pretreated RRMM

BySagar Lonial, MD,Karen L. Klugo, MD,Natalie Callander, MD

March 8th 2022

Natalie Callander, MD, presents the profile of a female patient with relapsed/refractory multiple myeloma who receives belantamab mafodotin and develops keratopathy.

Safety of Belantamab Mafodotin in Patients With RRMM

BySagar Lonial, MD,Karen L. Klugo, MD,Natalie Callander, MD

March 8th 2022

Karen L. Klugo, MD, describes what’s unique in terms of patient response to belantamab mafodotin as treatment for relapsed/refractory multiple myeloma and risk of ocular disease.

BCMA-Targeting Belantamab Mafodotin: Role in the Treatment Landscape of RRMM

BySagar Lonial, MD, FACP,Karen L. Klugo, MD,Natalie Callander, MD

February 28th 2022

The rationale for treating relapsed/refractory multiple myeloma with belantamab mafodotin, and studies investigating the drug’s potential in earlier treatment settings.

Treatment Approach for a 57-Year-Old Man With Triple-Class Refractory MM

BySagar Lonial, MD, FACP,Karen L. Klugo, MD,Natalie Callander, MD

February 28th 2022

Sagar Lonial, MD, FACP, highlights a novel treatment option available for a 57-year-old man whose disease progresses after 3 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.